Kantarjian et al53 assessed the efficacy and protection of dasatinib, as in contrast with imatinib, for the primary-line remedy of CML-CP. Five hundred and nineteen sufferers with freshly diagnosed CML-CP were randomly assigned to receive dasatinib in a dose of 100 mg when every day (259 individuals) or imatinib at https://elizabethx974qva8.blogolenta.com/profile